癫痫市场：KOL 洞察

本报告考察了全球癫痫市场并提供了市场概述，包括批准的治疗方法、管道趋势和未来前景。

目录

执行摘要

癫痫的未来治疗范例

研究目的

钠通道阻断剂

• 非处方疗法
  • 卡马西平相关抗癫痫药物
  • Vinpat（拉科酰胺、UCB）
  • Xcopri/Ontozry（cenobamate，SK Life Science）

神经调节剂

• 非处方疗法
  • Briviat（布瓦西坦，UCB）

GABA能机制

• 非处方疗法
  • 苯并二平（救援药物）
  • Tutalmy（加奈索酮，Marinus Pharmaceuticals）

其他作用机转

• 非处方疗法
  • Epidiolex/Epidyolex（大麻二酚，Jazz Pharmaceuticals）
  • Fintepra（芬氟拉明，UCB）
  • Fycompa（□崙帕奈、卫材）

迟到的产品

• 管道处理
  • Belviq（氯卡色林、卫材）
  • Soticlestat（武田）
  • Karizba Mate（SK 生命科学）

早期产品

• 管道处理
  • ACT-709478/NBI-827104（神经分泌生物科学）
  • XEN1101（Xenon Pharmaceuticals）
  • 克立咪唑（EPX-100，Epygenix Therapeutics）

未来的治疗范例

附录

KOLs see the potential in Marinus Pharmaceuticals' Ztalmy for treating Lennox-Gastaut syndrome, but in what other setting do they perceive it might provide value, and what factors could limit its uptake? Experts accept that Eisai's Fycompa is an effective treatment for both focal and generalized epilepsies, but what safety concerns do they express? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to KOL Bulletins.

Table of Contents

Executive summary (11)

Future treatment paradigm for epilepsy

Research objectives (1)

Sodium channel blockers (20)

• Marketed therapies (20)
  • Carbamazepine-related anti-seizure drugs (5)
  • Vimpat (lacosamide; UCB) (6)
  • Xcopri/Ontozry (cenobamate; SK Life Science) (9)

Neuromodulators (5)

• Marketed therapies (5)
  • Briviact (brivaracetam; UCB) (5)

GABAergic mechanisms (20)

• Marketed therapies (20)
  • Benzodiapines (rescue medications) (8)
  • Ztalmy (ganaxolone; Marinus Pharmaceuticals) (12)

Other modes of action (24)

• Marketed therapies (24)
  • Epidiolex/Epidyolex (cannabidiol; Jazz Pharmaceuticals) (8)
  • Fintepla (fenfluramine; UCB) (6)
  • Fycompa (perampanel; Eisai) (10)

Late-stage products (31)

• Pipeline therapies (31)
  • Belviq (lorcaserin; Eisai) (14)
  • Soticlestat (Takeda) (10)
  • Carisbamate (SK Life Science) (7)

Early-stage products (17)

• Pipeline therapies (17)
  • ACT-709478/NBI-827104 (Neurocrine Biosciences) (5)
  • XEN1101 (Xenon Pharmaceuticals) (7)
  • Clemizole (EPX-100; Epygenix Therapeutics) (5)

Future treatment paradigm (9)

Appendix (3)

• KOL details (3)
  • US KOLs (1)
  • European KOLs (1)